---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-164527"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2025-07-25T23:59:59+00:00"
generated_at: "2026-05-18T00:48:49.697548+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Edwards Lifesciences EVP Larry Wood to resign; Daniel Lippis to lead TAVR business

## Summary
- Larry Wood, Corporate VP and Group President of TAVR and Surgical Structural Heart, resigns effective Sept 1, 2025.
- Wood departs to accept a senior leadership role at another company outside cardiovascular.
- Daniel J. Lippis, current Corporate VP for Japan, Greater China, and Asia Pacific, will succeed as Corporate VP for TAVR.
- The transition is effective September 1, 2025.

## SEC filing metadata
- accession: 0001193125-25-164527
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2025-07-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000119312525164527/0001193125-25-164527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000119312525164527/d66195d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-164527
- JSON: https://secwatch.observer/filing/0001193125-25-164527.json
- Plain text: https://secwatch.observer/filing/0001193125-25-164527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.